BioSpace News Archive

Taysha Gene Therapies, Inc. announced its participation in virtual fireside chats for the 20th Annual Needham Virtual Healthcare Conference and the Chardan 5th Annual Manufacturing Summit.

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of previously disclosed clinical results from the successful OTO-313 Phase 1/2 trial at the upcoming American Neurotology Society’s 56 th Annual Spring Meeting, which is part of the Combined Otolaryngology Spring Meeting (COSM), to be held virtually April 7-11, 2021.

Acquisition to support the speed, efficiency and flexibility needed for mainstream global adoption of personalized cancer care and monitoring

Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the U.S. Food and Drug Administration (FDA) has approved the companys Investigational Device Exemption (IDE) application to begin the U.S. pivotal trial for the VenoValve.

Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will participate in a fireside chat and one-on-one investor meetings at the virtual 20th Annual Needham Healthcare Conference to be held April 12-15, 2021.

Teneobio, Inc., a clinical stage biotech company focused on the discovery and development of novel multi-specific biotherapeutic antibodies, reported the Phase I clinical entry and the dosing of patients with the bispecific JNJ-75348780 in a Phase I study (https://clinicaltrials.gov/ct2/show/NCT04540796), which is sponsored by Janssen Research & Development, LLC (Janssen)

Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, announced the successful completion of the safety run-in of the Stage 2 of the Phase 2 clinical study of prexigebersen, a liposomal Grb2 antisense, for the treatment of acute myeloid leukemia, in combination with frontline therapies, decitabine and venetoclax, in acute myeloid leukemia patients.

Oncolytics Biotech® Inc. announced that it will host a Key Opinion Leader webinar discussing AWARE-1 data, the immunotherapeutic effects of pelareorep in breast cancer, and its synergistic activity with CAR T cells in solid tumors.

Designed with nanoscale surface features, the CONSTRUX Mini Ti System is Orthofix’s first 3D-printed titanium (Ti) interbody introduced to the market.

Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, announced a poster presentation on safety and tolerability of twice daily administered poziotinib in patients with EGFR or HER2 exon 20 mutations.